Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

62.90 

3.16 5.3%

as of Apr 16 '14 16:00

52 Week Range:

23.87 80.42


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Ligand Pharmaceuticals, Inc. was incorporated in Delaware in 1987. It is a biopharmaceutical company engaged in developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. The Company has evaluated ASC 280 and has identified two reportable segments: the development and commercialization of drugs using Captisol technology by CyDex Pharmaceuticals, Inc. and the biopharmaceutical company. With its portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, the Company offers investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. It has multiple partnered programs in its portfolio that are either in or nearing the regulatory approval process. GSK’s Promacta (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP. The Company currently receives royalty revenues from Pfizer, Inc., or Pfizer, for sales of the pain therapeutic Avinza. The drug is also marketed in Spain under the brand name Conbriza through a co-promotion with Almirall, an international pharmaceutical company based in Spain. The Company currently has no manufacturing facilities. It currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a supplier of active pharmaceutical ingredients, or APIs and API intermediates located in Portugal. Its competitive position also depends upon its ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales. The Company is subject to rigorous regulation by federal and various state authorities, including the FDA.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

Item Name Dec '03 Dec '04 Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13
Equity (BVPS) -1.88
-5.11
-8.05
0.35
0.31
0.11
0.03
0.18
0.42
1.31
2.42
growth rate 0.0% 0.0% 100.0% -11.4% -64.5% -72.7% 500.0% 133.3% 211.9% 84.7%
Earnings BIT -94.41
-44.91
36.34
-174.27
-53.46
-97.52
-9.87
-15.40
-2.95
-3.87
9.21
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Avg.PE -7.90
-46.30
-17.00
-15.70
-20.90
-3.20
-34.50
-15.00
22.99
-118.50
121.95
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 100.0%
ROA -13.10
-14.20
-11.30
-9.90
112.80
-56.90
-1.20
-9.50
10.30
-0.50
10.90
growth rate 0.0% 0.0% 0.0% 100.0% -100.0% 0.0% 0.0% 100.0% -100.0% 100.0%
ROE -51.80
36.10
36.70
-142.60
997.70
-1,046.50
-69.00
-365.80
536.00
-3.00
30.00
growth rate 100.0% 1.7% -100.0% 100.0% -100.0% 0.0% 0.0% 100.0% -100.0% 100.0%
Balance Sheet Dec '03 Dec '04 Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13
Acct.Receivable 0.00
0.60
1.00
6.10
4.60
2.20
growth rate 66.7% 510.0% -24.6% -52.2%
Cur.Assets 93.90
68.20
37.00
32.20
23.80
24.90
growth rate -27.4% -45.8% -13.0% -26.1% 4.6%
Total Assets 171.40
141.80
75.60
120.60
104.30
104.70
growth rate -17.3% -46.7% 59.5% -13.5% 0.4%
Cash 28.80
16.00
3.30
7.00
12.40
11.60
growth rate -44.4% -79.4% 112.1% 77.1% -6.5%
Inventory 0.00
0.00
0.00
1.30
1.70
1.40
growth rate 30.8% -17.7%
Cur.Liabilities 70.60
52.20
33.50
43.60
35.40
28.90
growth rate -26.1% -35.8% 30.2% -18.8% -18.4%
Liabilities 181.80
138.10
80.40
112.40
77.80
55.10
growth rate -24.0% -41.8% 39.8% -30.8% -29.2%
LT Debt 170.05
171.09
170.18
2.16
0.63
49.70
36.30
0.00
20.30
13.40
0.00
growth rate 0.6% -0.5% -98.7% -71.0% 7,826.6% -27.0% -100.0% -34.0% -100.0%
Equity -98.07
39.70
41.46
1.98
3.70
3.50
8.20
26.50
49.60
growth rate 100.0% 4.4% -95.2% 86.9% -5.4% 134.3% 223.2% 87.2%
Common Shares 12.18
16.58
15.71
19.76
116.66
19.51
19.56
20.16
20.47
growth rate 36.1% -5.3% 25.8% 490.4% -83.3% 0.3% 3.1% 1.5%
Cash Flow Statement Dec '03 Dec '04 Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13
Purch/Sale of Prop 6.92
3.60
35.60
1.78
0.44
0.40
0.40
0.70
-0.50
0.60
0.40
growth rate -48.0% 888.9% -95.0% -75.3% -9.1% 0.0% 75.0% -100.0% 100.0% -33.3%
Cash Dividends 0.00
0.00
0.00
0.00
252.74
0.00
0.00
0.00
0.00
0.00
growth rate -100.0%
Cash From OA 0.31
5.75
8.37
-138.52
-97.73
-20.63
-33.80
-27.07
-1.17
0.20
20.70
growth rate 1,754.8% 45.6% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 10,250.0%
FCF -6.61
2.15
-27.23
-140.30
-98.17
-21.10
-34.30
-28.40
-1.30
-0.40
20.30
growth rate 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Income Statement Dec '03 Dec '04 Dec '05 Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13
Sales 81.12
112.11
10.22
3.98
12.89
27.30
38.90
23.50
30.00
31.40
49.00
growth rate 38.2% -90.9% -61.1% 223.9% 111.8% 42.5% -39.6% 27.7% 4.7% 56.1%
Op.Income -97.30
-10.00
-29.30
-0.70
0.20
14.90
growth rate 0.0% 0.0% 0.0% 100.0% 7,350.0%
IBT -97.50
-9.90
-15.40
-3.60
-3.90
9.20
growth rate 0.0% 0.0% 0.0% 0.0% 100.0%
Net Income -98.10
-1.90
-10.40
9.70
-0.50
11.40
growth rate 0.0% 0.0% 100.0% -100.0% 100.0%
EPS -8.02
-1.85
-2.92
-4.21
-2.13
-6.18
-0.10
-0.53
0.49
-0.03
0.55
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 100.0%
Gross Profit 93.85
10.22
3.98
12.89
27.30
38.90
23.50
25.10
27.80
43.20
growth rate -89.1% -61.1% 223.9% 111.8% 42.5% -39.6% 6.8% 10.8% 55.4%
R&D 30.80
39.90
22.10
10.30
10.80
9.30
growth rate 29.6% -44.6% -53.4% 4.9% -13.9%

Quarterly Statements

Item Name Dec '12 Mar '13 Jun '13 Sep '13 Dec '13
Balance Sheet
Acct.Receivable 4.60
4.60
0.70
5.50
2.20
growth rate 0.0% -84.8% 685.7% -60.0%
Cur.Assets 23.80
17.70
14.60
16.60
24.90
growth rate -25.6% -17.5% 13.7% 50.0%
Total Assets 104.30
98.40
99.60
101.70
104.70
growth rate -5.7% 1.2% 2.1% 3.0%
Cash 12.40
5.00
5.90
3.30
11.60
growth rate -59.7% 18.0% -44.1% 251.5%
Inventory 1.70
2.80
2.30
1.80
1.40
growth rate 64.7% -17.9% -21.7% -22.2%
Cur.Liabilities 35.40
33.00
32.60
32.50
28.90
growth rate -6.8% -1.2% -0.3% -11.1%
Liabilities 77.80
67.80
60.30
56.90
55.10
growth rate -12.9% -11.1% -5.6% -3.2%
LT Debt 13.40
10.60
6.30
0.00
0.00
growth rate -20.9% -40.6% -100.0%
Equity 26.50
30.60
39.30
44.80
49.60
growth rate 15.5% 28.4% 14.0% 10.7%
Common Shares 20.16
21.34
21.44
21.53
20.47
growth rate 5.9% 0.5% 0.4% -4.9%
Cash Flow Statement Dec '12 Mar '13 Jun '13 Sep '13 Dec '13
Purch/Sale of Prop 0.00
0.10
0.10
0.10
growth rate 0.0% 0.0%
Cash Dividends 0.00
growth rate
Cash From OA 2.10
6.90
8.70
12.00
growth rate 228.6% 26.1% 37.9%
FCF 2.00
3.20
-0.50
11.90
growth rate 60.0% -100.0% 100.0%
Income Statement Dec '12 Mar '13 Jun '13 Sep '13 Dec '13
Sales 13.60
11.70
9.60
13.00
14.70
growth rate -14.0% -18.0% 35.4% 13.1%
Op.Income 4.30
3.90
1.50
3.10
6.40
growth rate -9.3% -61.5% 106.7% 106.5%
IBT 1.00
1.40
3.80
2.00
2.00
growth rate 40.0% 171.4% -47.4% 0.0%
Net Income 1.10
1.50
6.10
2.00
1.90
growth rate 36.4% 306.7% -67.2% -5.0%
EPS 0.05
0.07
0.30
0.09
0.09
growth rate 40.0% 328.6% -70.0% 0.0%
Gross Profit 11.30
11.00
8.40
10.50
13.40
growth rate -2.7% -23.6% 25.0% 27.6%
R&D 2.50
2.50
2.00
2.40
2.40
growth rate 0.0% -20.0% 20.0% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (79.32)

YOY Growth Grade:

E (32.04)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 18.93 142.86 32.90
EPS / Growth 16.5% 0.55 30.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 16.5% 32.2% 43.1%
Future PE 18.93 38.72 46.03
Future EPS 2.53 8.95 19.85
Value Price
MOS
11.85
-81.2%
85.64
36.2%
225.80
259.0%
MOS Price 5.93 42.82 112.90
IRT 18.61 12.05 9.94

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

Access denied

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE.